Regeneron Pharmaceuticals (REGN) Earnings Date, Estimates & Call Transcripts → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free REGN Stock Alerts $890.68 -15.86 (-1.75%) (As of 04/25/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Earnings SummaryUpcoming Earnings DateMay. 2Before Market OpensConfirmedActual EPS (Feb. 2) $11.86 Beat By $1.13 Consensus EPS (Feb. 2) $10.73 Read Call TranscriptListen to Call Get Regeneron Pharmaceuticals Earnings AlertsEnter your email address below to receive the latest news and earnings results for REGN and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueREGN Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.REGN Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Insider FinancialThousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage" Regeneron Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242$7.48$8.05$7.77Q2 20242$9.59$9.67$9.63Q3 20242$9.80$11.42$10.61Q4 20242$7.72$10.57$9.15FY 20248$34.59$39.71$37.15REGN Earnings Date and InformationRegeneron Pharmaceuticals last announced its quarterly earnings data on February 2nd, 2024. The biopharmaceutical company reported $11.86 EPS for the quarter, topping the consensus estimate of $10.73 by $1.13. The business had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. Its revenue for the quarter was up .6% on a year-over-year basis. Regeneron Pharmaceuticals has generated $34.75 earnings per share over the last year ($34.75 diluted earnings per share) and currently has a price-to-earnings ratio of 25.6. Earnings for Regeneron Pharmaceuticals are expected to grow by 4.02% in the coming year, from $38.80 to $40.36 per share. Regeneron Pharmaceuticals has confirmed that its next quarterly earnings report will be published on Thursday, May 2nd, 2024. Regeneron Pharmaceuticals will be holding an earnings conference call on Thursday, May 2nd at 8:30 AM Eastern. Interested parties can register for or listen to the call.. Read More Regeneron Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 5/2/2024Confirmed)------- 2/2/2024Q4 2023$10.73$11.86+$1.13$10.17$3.29 billion$3.43 billion 11/2/2023Q3 2023$9.39$10.17+$0.78$11.45$3.23 billion$3.36 billion 8/3/2023Q2 2023$8.48$10.24+$1.76$9.08$3.02 billion$3.16 billion 5/4/2023Q1 2023$7.71$8.44+$0.73$9.71$2.92 billion$3.16 billion2/3/2023Q4 2022$8.18$12.56+$4.38$11.42$3.11 billion$3.41 billion 11/3/2022Q3 2022$8.55$9.98+$1.43$8.30$2.79 billion$2.94 billion Get the Latest News and Ratings for REGN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 8/3/2022Q2 2022$8.53$9.77+$1.24$12.07$2.80 billion$2.86 billion 5/4/2022Q1 2022$9.37$11.49+$2.12$14.37$2.69 billion$2.97 billion 2/4/2022Q4 2021$18.49$23.72+$5.23$27.75$4.49 billion$4.95 billion 11/4/2021Q3 2021$9.81$15.37+$5.56$16.41$2.80 billion$3.45 billion 8/5/2021Q2 2021$8.81$25.80+$16.99$27.97$3.90 billion$5.14 billion 5/6/2021Q1 2021$7.78$9.89+$2.11$10.09$2.69 billion$2.53 billion Regeneron Pharmaceuticals Earnings - Frequently Asked Questions When is Regeneron Pharmaceuticals's earnings date? Regeneron Pharmaceuticals has confirmed that its next quarterly earnings data will be published on Thursday, May 2nd, 2024. Learn more on REGN's earnings history. Did Regeneron Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Regeneron Pharmaceuticals (NASDAQ:REGN) reported $11.86 earnings per share (EPS) to beat the analysts' consensus estimate of $10.73 by $1.13. Learn more on analysts' earnings estimate vs. REGN's actual earnings. How can I listen to Regeneron Pharmaceuticals's earnings conference call? The conference call for Regeneron Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call How can I read Regeneron Pharmaceuticals's conference call transcript? The conference call transcript for Regeneron Pharmaceuticals's latest earnings report can be read online. Read Transcript How much revenue does Regeneron Pharmaceuticals generate each year? Regeneron Pharmaceuticals (NASDAQ:REGN) has a recorded annual revenue of $13.12 billion. How much profit does Regeneron Pharmaceuticals generate each year? Regeneron Pharmaceuticals (NASDAQ:REGN) has a recorded net income of $3.95 billion. REGN has generated $34.75 earnings per share over the last four quarters. What is Regeneron Pharmaceuticals's price-to-earnings ratio? Regeneron Pharmaceuticals (NASDAQ:REGN) has a trailing price-to-earnings ratio of 25.63 and a forward price-to-earnings ratio of 22.96. The price/earnings-to-growth ratio is 2.61. What is Regeneron Pharmaceuticals's EPS forecast for next year? Regeneron Pharmaceuticals's earnings are expected to grow from $38.80 per share to $40.36 per share in the next year, which is a 4.02% increase. More Earnings Resources from MarketBeat Related Companies: VRTX Earnings BMY Earnings SNY Earnings GSK Earnings ZTS Earnings TAK Earnings RPRX Earnings ABT Earnings BGNE Earnings CTLT Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future OutlookCSX Co.: The Railroad Powering Ahead with an Earnings Beat What's Driving Tesla Lower Ahead of its Earnings?Blackrock vs. State Street: Earnings in a Volatile MarketWhat to Expect From the Q1 Earnings Reporting SeasonLululemon Stock Implodes Post Earnings, Guidance Muted This page (NASDAQ:REGN) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersFed launches fourth dollar overhaulStansberry ResearchThe AI stock to buy right nowStockEarningsBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the MarketsKeep Your Eyes on This Power-Mad PoliticianAltimetryThe Next Nvidia?InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
